熱門資訊> 正文
Altimune直接发行价为7500万美元
2026-01-28 12:39
- Altimmune (ALT) entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17.05M shares pursuant to a registered direct offering.
- The offering is expected to result in gross proceeds of ~$75M.
- All the shares and pre-funded warrants in the offering are being offered by Altimmune.
- The offering is expected to close on or about January 29, 2026.
- The net proceeds will be used to fund preparation for its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis as well as for working capital and general corporate purposes.
- The stock price traded 3% higher on Tuesday during after-market hours of trading.
More on Altimmune
- Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen
- Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates
- Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH - Slideshow
- Altimmune gains on FDA breakthrough designation for MASH therapy
- Altimmune posts mid-stage trial data showing antifibrotic activity of lead asset in MASH
推薦文章
華盛早報 | 特朗普再發驚人言論！美元跌至四年低谷，金價續創新高；聯合健康績后重挫近20%
1月28日外盤頭條：美元跌至四年低點 特朗普稱不擔心 谷歌推出低價版AI Plus 特朗普關税落地概率不足三成
美股機會日報 | 美光擬豪擲240億美元擴產存儲芯片！聯合健康遭雙重利空打擊，盤前暴跌15%
再出手飆漲超60%！特朗普政府重金入股美稀土公司，這份「關鍵礦產公司名單」請收好
華盛早報 | 特朗普突發貿易威脅！對韓國加税至25%；白銀「深V」閃崩后又急升
新股申購 | 國恩科技今起招股！一手入場費8484.71港元
特朗普政府16億美元入股美國稀土公司，佈局稀土供應鏈
摩根士丹利和美銀看好新興市場套利交易 去年回報已創2009年以來最強
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
